text: No recommendations are made for or against specific<unk> –C or<unk> -HDL–C<unk>  for the 
  primary prevention or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) given the lack of evidence on titration of<unk> -lowering therapy to specific<unk> .
option_0: Blood cholesterol LDL and non-HDL treatment goals
option_1: High cholesterol primary prevention
option_2: High cholesterol secondary prevention
option_3: High density lipoprotein future or investigational therapies
option_4: Chronic stable angina treatment lipid management
option_5: High density lipoprotein medical therapy
option_6: Rosiglitazone detailed information
option_7: Diabetes primary prevention of cardiovascular events